[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
The Composition of the Board of Directors and its Committees meets the requirements of the Euronext code for the independence of directors.
After gaining a PhD in pharmacology from the University of Dijon, Philippe Genne began his scientific career as a project leader at Debiopharm where he oversaw a clinical development program related to multi-drug resistance inhibitors. He also worked as a research associate at Glaxo-Welcome.
His preclinical research experience in oncology also encompasses phase I and phase II clinical trials in conjunction with Inserm. In 1995, he founded Oncodesign in Dijon. Since then, he has earned a reputation as a serial entrepreneur in life sciences. As well as being Chairman of Oncodesign, a company specialized in the discovery of new therapies and European leader in the preclinical evaluation of anti-cancer therapies, he is also Chairman of the Pharmimage platform, which he set up in 2008. Philippe Genne is well known for his activities right across the life sciences value chain. In 2012, he helped set up the French association of life sciences service and innovation companies (AFSSI). Since 2018, he is also the Vice-President of the SMEs College at Medicen.
Jan Hoflack obtained a PhD in organic chemistry from the University of Ghent in Belgium before gaining solid experience and taking on executive positions at Marion Merrell Dow in Strasbourg (France), Novartis in Basel (Switzerland) and AstraZeneca in Gothenburg (Sweden). He was then appointed Vice President, Medicinal Chemistry and Biosciences at Johnson and Johnson Pharmaceutical R&D (Janssen) in Beerse (Belgium). He joined Oncodesign in 2009 as a partner and Chief Scientific Officer and was tasked with Setting up and developing full Drug Discovery capability. Drawing on his 31 years of R&D experience, including 22 years in the pharmaceutical industry, Jan invented the Nanocyclix chemistry technology that has provided access to next-generation kinase inhibitors.
Fabrice Viviani holds a PhD in organic chemistry and an MA in biology from Pierre-and-Marie-Curie University (UPMC). He started his career as a biologist and was responsible for research project and clinical teams in infectiology, before turning his attention to oncology research at Aventis’ oncology therapy department. He was then appointed Sanofi-Aventis’ Vice President for R&D, having managed several departments (medicinal chemistry and biology for exploratory research and internal medicine, early-to-candidate DPU). At GSK he took charge of the discovery biology group at the François Hyafil research center. To date, he has been involved in discovering and developing over 20 preclinical and clinical drug candidates.
Stéphane Gerart is an engineer from the Ecole Polytechnique and the INA-PG and holds a PhD in immunology from Paris Descartes University. He begins his career as a business development consultant within the Consulting Firm Novoptim, a partner of choice in the strategic, marketing and operational support of fast-growing health life sciences companies on the European market. He then joins SOPHiA GENETICS in Canada. His mission as the country business development manager of this pioneer company in its field allowed him to acquire expertise in artificial intelligence and related applications. Back in France, as head of corporate business development for SOPHiA GENETICS, he is exposed to the booming ecosystem of new technologies in the healthcare world. He joins Oncodesign in 2020 to be responsible of the Artificial Intelligence Business Unit.
Thierry Billoué has over 20 years’ professional experience to his name and has worked in a variety of business sectors, including automotive, consumer electronics, IT services and IT security. He has supported mid-sized businesses (60 – 750 employees, revenue of €10 million – €150 million) pursuing a strategy of far-reaching transformation (exponential growth, business creation, turnaround phase, etc.). Today Thierry has responsibility for the organizational and human resources aspects of Oncodesign’s transformation as part of its development and growth strategy. He believes that all organizations, and all employees, are capable of transforming themselves and embracing change provided that they understand the reasons behind it, so that they strive for and effect this change themselves.
Arnaud Lafforgue has close to 20 years’ experience in consulting and management roles in both financial and operational functions. During his past nine years with Grant Thornton, his duties have included being Head of Transaction Services responsible for the Operational Deal Services offering. In this role, he supported various businesses and investment funds with their divestments, acquisitions, reorganizations and post-acquisition integrations. He also led a number of information system overhaul projects and complex reorganization projects in France and further afield – including in Morocco and the United Kingdom. Arnaud Lafforgue graduated from the EM-Lyon business school and holds a master’s degree in management from the University of Paris X. His career began as an organizational consultant with Arthur Andersen, and he then joined Kroll Talbot Hughes, a specialist in operational and financial corporate restructuring.
The beginning of my career was within the Fournier Group (independent French family group) where I stayed almost 10 years. I had the opportunity to accompany the different companies of the group in France and internationally, both within multidisciplinary project teams and as a single expert on technical and specialized law issues (commercial law, health law, economic law, etc.).
I was then given the opportunity to work in an international business law firm based in Luxembourg, where I advised large multinational groups on restructuring operations.
My career continued with the Vétoquinol Group (an independent family group exclusively dedicated to animal health – 10th amongst worldwide laboratories) as Legal Affairs Manager. During this experience, I was able to advise my various internal clients on topics such as acquisition files, strategic partnerships, license agreements, distribution contracts as well as other files in France, in the USA, Canada or the UK.
Before joining Oncodesign in May 2021, I held, within the URGO Group, the position of Legal Director at URGO MEDICAL AND HEALTHCARE and supervised a team of 5 people acting for the French and foreign entities of the Urgo division. I had the opportunity to work, in particular and lead the negotiations for a very nice public-private consortium with the mission to develop an innovative therapeutic solution in wound healing.
Karine Lignel is an Agro-Food Engineer (ENSIA). She holds a Master’s degree in Finance and Management (IGIA). She started her career in the food industry where she held technical and management positions. She has been working in R&D, production, quality and innovation for 7 years at Barry-Callebaut. At the age of 25, she was in charge of a chocolate production plant staffed with 50 employees.
In 2000, Karine Lignel switched to Venture Capital.
This job, which she had exercised for more than 20 years, allowed her to continue to use her scientific knowledge while sharpening her analytical, financial and, above all, coaching skills.
This role of support in growth and sustainability is one of the fundamental pillars of the financial shareholder: it guides and influences the governance bodies in their strategic decisions (commercial, acquisition, management). These decisions are generally supported by financing.
Karine Lignel has accompanied more than sixty technology companies, mostly in the health industry, and has been a member of more than thirty boards (of directors or supervisory boards). In particular, she has assisted the IPO of Nanobiotix, Oncodesign and Medincell.
Since 2008, Karine Lignel has been accompanying Oncodesign as a representative of “Crédit Mutuel Innovation”.
Her various and complementary skills will help support and expand the company’s growth.